ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS BISPECIFIC (CD38 x CD47) ANTIBODY INNATE CELL MODULATOR, ISB 1442
/PRNewswire/ -- Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies in oncology, today announced...